The effect of oral micronized progesterone on first trimester screening test markers and neonatal outcome
Abstract
Objective:
It was aimed to investigate whether or not nuchal translucency(NT) thickness,
maternal serum free beta-human chorionic gonadotropin(β-hCG) and
pregnancy-associated plasma protein-A(PAPP-A) levels may affected by the use of
oral micronized progesterone(OMP) in first trimester pregnancies. Also we aimed
to evaluate pregnancy outcome in pregnant women using OMP.
Method:
This study was performed retrospectively including 1192 pregnant women, between
January 2015 and August 2017. Body mass index(BMI), maternal and gestational
age, levels of maternal serum PAPP-A and free β-hCG, NT measurement and the
crown–rump length(CRL), fetal sex, fetal birth weight, Apgar score
5thminute<7 and admission to neonatal intensive care unit(NICU) were
evaluated.
Results:
Maternal characteristics, ultrasound and biochemical parameters, fetal characteristics
and neonatal outcome were evaluated. There was no statistically significant
difference for maternal age, BMI, gestational age, PAPP-A, β-hCG, CRL, NT
thickness, fetal sex, fetal birth weight, Apgar score 5th minute <7 and the
number of admission to NICU during the first 28 days.
Conclusions: Our results suggest that in clinical practice, 1) it seems that using OMP cannot affect on NT, CRL and birth weight. 2) OMP cannot adversely affect on production of PAPP-A and β-hCG in vivo. 3) NT, serum PAPP-A and β-hCG levels and MoM values, which are markers of the first trimester screening test, do not change by using OMP. Therefore using OMP cannot affect reliability of the first trimester screening test in pregnancy with threatened abortion. 4) OMP does not look like adversely affect on poor neonatal outcome.
Keywords
References
- 1. Alldred SK, Takwoingi Y, Guo B, et all. First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening. Cochrane Database of Systematic Reviews 2017: 3.
- 2. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. Multicenter study of first-trimester screening for trisomy 21 in 75821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol. 2005; 25: 221–6.
- 3. Liao AW, Heath V, Kametas N, Spencer K, Nicolaides KH. First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. Hum Reprod. 2001; 16: 501–1504.
- 4. Walch KT, Huber JC. Progesterone for recurrent miscarriage: truth and deceptions. Best Pract Res Clin Obstet Gynaecol. 2008; 22: 375-89.
- 5. Sotiriadis A, Papatheodorou S, Makrydimas G. Threatened miscarriage: evaluation and management. Brid Med J. 2004; 329: 152.
- 6. Czajkowski K, Sienko J, Mogilinski M, et all. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil Steril. 2007; 87: 613.
- 7. Weiss JL, Malone FD, Vidaver J, et al. Threatened abortion: a risk factor for poor pregnancy outcome, a population-based screening study. Am J Obstet Gynecol 2004; 190: 745.
- 8. Alp M, Diclehan O. Tekrarlayan spontan abortusları olan çiftlerde genetik araştırmalar. Dicle Tıp Derg. 2006; 33: 71-80.
Details
Primary Language
English
Subjects
Health Care Administration
Journal Section
Research Article
Authors
İlknur Col Madendag
This is me
0000-0001-6700-2236
Mehmet Ak
This is me
0000-0003-3384-0586
Erdem Sahin
This is me
0000-0001-9492-6223
Mefkure Eraslan Sahin
This is me
0000-0001-6484-9132
Publication Date
June 11, 2019
Submission Date
September 7, 2018
Acceptance Date
January 4, 2019
Published in Issue
Year 2019 Volume: 46 Number: 2